Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Amphion enjoys improvement in equity markets

Amphion enjoys improvement in equity markets

Amphion Innovations (LON:AMP), the incubator for technology companies, gave a guardedly optimistic assessment of its prospects in the first half.

The planned listing of partner company Kromek, the scanners business, points to a favourable turn in the equity market and will give Amphion’s 13.3% stake an objective valuation.

It may also make it easier for its other fledglings to access capital to continue their development.

One of its firms, WellGen, has done this via the award of a phase-one SBIR grant by the National Institutes of Health.

The grant will help it progress the clinical investigation of its proprietary natural extracts in controlling type-two diabetes.

Amphion said it remains confident the DataTern business can generate “a substantial profit” from infringers of its intellectual property. That said the legal process has slowed.

The financials reveal the group generated revenues of US$264,638 during the six months to June 30 – in line with the final half of last year – and posted an operating loss of just over US$1mln. The net asset value as at the period-end was 12 cents (8p).

The statement did come with a cautionary statement on the group’s financial position as it said support for Amphion in the first half “has continued to be provided, for the most part, by loans from the directors and additional contributions from the management team”.

View full AMP profile View Profile

Amphion Innovations Plc Timeline

Related Articles

Runner
January 17 2017
The shares ended 2016 at 8.89p having started it at 3.66p. Backers have consistently exercised warrants to acquire more shares.
eSports player at a Gfinity event
August 01 2017
eSports are tipped to generate more than £1bn a year in a global revenue by 2020, while audience numbers are set to go through the roof too
VW-plant.jpg
October 10 2017
Mike McAuliffe reckons the company's technology is 'tremendous', it is just a case of making the most of it commercially

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use